| [17] |
Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer[J]. J Clin Oncol, 2009, 27(22): 3611-3619.
|
| [1] |
Pal SK, Lau SK，Kruper L, et al. Papillary carcinoma of the breast: an overview[J]. Breast Cancer Res Treat, 2010, 122(3): 637-645.
|
| [2] |
林敏，侯刚，宋璐，等. 乳腺浸润性乳头状癌的临床病理学特征分析[J]. 实用肿瘤杂志，2021, 36(2): 163-166.
|
| [3] |
Lakhani SR, Ellis IO, Schnitt SJ, et al. World Health Organization classification of tumors of the breast[M]. Lyon: LARC Press, 2012: 64.
|
| [4] |
汪庆余，雷瑛. 乳腺乳头状癌临床病理诊断分析[J]. 实验与检验医学，2009, 27(1)：13-14.
|
| [5] |
Bhosale SJ, Kshirsagar AK, Sulhyan SR, et al. Invasive papillary breast carcinoma[J]. Case Rep Oncol, 2010, 3(3): 410-415.
|
| [6] |
Eremia IA, Ciobanu M, Tenea T, et al. Invasive papillary carcinoma of the mammary gland: histopathologic and immunohistochemical aspects[J]. Rom J Morphol Embryol, 2012, 53(3): 811-815.
|
| [7] |
付丽，傅西林. 乳腺肿瘤病理诊断学[M]. 北京：人民卫生出版社，2008: 66-69.
|
| [8] |
Akagi T, Kinoshita T, Shien T, et al. Clinical and pathological features of intracystic papillary carcinoma of the breast[J]. Surg Today, 2009, 39(1): 5-8.
|
| [9] |
Otsuki Y, Yamada M, Shimizu S, et al. Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases [J]. Pathol Int, 2010, 57(7): 421-429.
|
| [10] |
Zheng YZ, Hu X, Shao ZM, et al. Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: a SEER population-based study[J]. Sci Rep, 2016, 6: 24 037.
|
| [11] |
于汀，孙海涛，张艺，等. 乳腺导管内乳头状瘤、非典型乳头状瘤与导管内乳头状癌诊断与鉴别诊断[J]. 现代生物医学进展，2009, 9(12): 2316-2318.
|
| [12] |
龚西騟，丁华野．乳腺病理学[M]．北京：人民卫生出版社，2009：451-453.
|
| [13] |
蔡钰，韦慧. 乳腺恶性叶状肿瘤2例并文献复习[J]. 影像研究与医学应用，2019, 3(4): 255-256.
|
| [14] |
耿珊珊，许旭，顾林，等. 72例乳腺浸润性乳头状癌的临床分析[J]. 中国肿瘤临床，2011，38(6): 349-352.
|
| [15] |
韩琼，吴斌，袁茂林. 乳腺浸润性乳头状癌预后影响因素分析[J]. 临床外科杂志，2020, 28(2)：41-44.
|
| [16] |
Roy V, LaPlant BR, Gross GG, et al. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531) [J]. Ann Oncol，2009, 20(3)：449-453.
|